Fundrise Innovation Fund Plunges 33% After Citron Research Short Attack

The Fundrise Innovation Fund, a publicly traded venture capital vehicle with stakes in high-profile private companies like Anthropic and SpaceX, saw its shares collapse by roughly one-third in a single trading session. The sharp reversal was triggered directly by a short report from Citron Research, which publicly announced its bearish position against the fund. This move represents a significant and immediate test of confidence for a novel investment structure that offers retail investors exposure to late-stage private tech unicorns.

The fund, which began trading earlier this year, had previously attracted attention for its portfolio, which includes coveted stakes in artificial intelligence leader Anthropic and aerospace giant SpaceX. Citron's decision to short the fund introduces intense scrutiny on its valuation methodology, fee structure, and the liquidity premium—or discount—applied to its underlying private holdings. The dramatic sell-off suggests the market is highly sensitive to perceived vulnerabilities in these new public-private investment hybrids.

The fallout places immediate pressure on Fundrise to defend its model and transparency. It also signals to other similar funds that they may face aggressive scrutiny from short sellers who question the translation of private market valuations to public market prices. The event highlights the inherent risks and volatility when complex, illiquid private assets are packaged for daily public trading, raising questions about suitability for mainstream investors during periods of market stress.